Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Develop Drugs for People, Not Just Bodies

December 1, 2013

A patient-centric approach to drug development delivers the benefits that actually create value, writes Charlotte Vansgaard and Mikkel Brok-Kristensen.

FDA Pursues Delicate Balancing Act

December 1, 2013

The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.

Complementing Personalized Medicines

November 26, 2013

Mollie Roth discusses how complementary diagnostics can improve disease management and optimize therapy.

Pharm Exec Roundtable on Market Access

November 25, 2013

Pharm Exec convenes a diverse panel of experts to identify the key markers of common ground: its time, people, and money against that greatest intangible—hope.

Clinical Trial Sponsors Struggle with Data Disclosure Requirements

November 25, 2013

Research sponsors argue that widening access to patient level data from clinical trials will undermine patient privacy and incentives for new drug development.

What Does the UK's 'New' PPRS Mean for Value-Based Pricing?

November 20, 2013

Leela Barham ponders the future of VBP in the light of a new PPRS deal between industry and the UK government.

Clearing the Emerging Market Hurdles

November 18, 2013

Despite the long-held promise of the emerging markets, dominance in these territories has eluded Big Pharma. Hussain Mooraj addresses the key issues and offers a strategy for success.

Get Real: Preparing for the Real World Evidence Future

November 12, 2013

Why Real World Evidence (RWE) is here to stay, and what you need to do to integrate it into your business strategy as painlessly as possible.

Brazil Improves Access to Experimental Drugs

November 11, 2013

New regulation offers drug options for patients with rare, severe, or debilitating illnesses.

ADVERTISEMENT

Click here